NO20081086L - Makrosykliske peptider som HCV NS3-proteaseinhibitorer - Google Patents
Makrosykliske peptider som HCV NS3-proteaseinhibitorerInfo
- Publication number
- NO20081086L NO20081086L NO20081086A NO20081086A NO20081086L NO 20081086 L NO20081086 L NO 20081086L NO 20081086 A NO20081086 A NO 20081086A NO 20081086 A NO20081086 A NO 20081086A NO 20081086 L NO20081086 L NO 20081086L
- Authority
- NO
- Norway
- Prior art keywords
- hcv
- protease inhibitors
- macrocyclic peptides
- protease
- macrocyclic
- Prior art date
Links
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 241000711549 Hepacivirus C Species 0.000 abstract 3
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70425605P | 2005-08-01 | 2005-08-01 | |
| US72450905P | 2005-10-07 | 2005-10-07 | |
| PCT/US2006/029635 WO2007016441A1 (en) | 2005-08-01 | 2006-07-28 | Macrocyclic peptides as hcv ns3 protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20081086L true NO20081086L (no) | 2008-04-30 |
Family
ID=37404447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20081086A NO20081086L (no) | 2005-08-01 | 2008-02-29 | Makrosykliske peptider som HCV NS3-proteaseinhibitorer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8278322B2 (pt) |
| EP (1) | EP1913016B1 (pt) |
| JP (1) | JP4705984B2 (pt) |
| KR (1) | KR20080036598A (pt) |
| AU (1) | AU2006275605B2 (pt) |
| BR (1) | BRPI0614205A2 (pt) |
| CA (1) | CA2615896C (pt) |
| CR (1) | CR9731A (pt) |
| EC (1) | ECSP088157A (pt) |
| IL (1) | IL189166A0 (pt) |
| MA (1) | MA29757B1 (pt) |
| MX (1) | MX2008001588A (pt) |
| NO (1) | NO20081086L (pt) |
| NZ (1) | NZ565269A (pt) |
| RU (1) | RU2008107972A (pt) |
| WO (1) | WO2007016441A1 (pt) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| CA2606195C (en) | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
| WO2007003135A1 (en) * | 2005-07-04 | 2007-01-11 | Zheng-Yun Zhan | Ruthenium complex ligand, ruthenium complex, carried ruthenium complex catalyst and the preparing methods and the use thereof |
| NZ565269A (en) | 2005-08-01 | 2010-03-26 | Merck & Co Inc | Macrocyclic peptides as HCV NS3 protease inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2007309546A1 (en) | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
| CA2667146C (en) | 2006-10-24 | 2016-01-19 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| AU2007309488B2 (en) * | 2006-10-24 | 2012-10-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| US8377874B2 (en) | 2006-10-27 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| BRPI0718161A2 (pt) * | 2006-10-27 | 2013-11-26 | Merck & Co Inc | Composto, composição farmacêutica, e, uso do composto. |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2672250C (en) | 2006-12-20 | 2013-04-30 | Ian Stansfield | Antiviral indoles |
| GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2481807A3 (en) | 2007-03-09 | 2013-04-03 | Merck Sharp & Dohme Corp. | In vivo HCV resistance to anti-viral inhibitors |
| JP2010533699A (ja) | 2007-07-17 | 2010-10-28 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Ｃ型肝炎感染症の治療のための大環状インドール誘導体 |
| AU2008277377B2 (en) * | 2007-07-19 | 2013-08-01 | Msd Italia S.R.L. | Macrocyclic compounds as antiviral agents |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| US8304385B2 (en) | 2007-11-14 | 2012-11-06 | Enanta Pharmaceuticals, Inc. | Macrocyclic tetrazolyl hepatitis C serine protease inhibitors |
| EP2224801A4 (en) | 2007-12-14 | 2011-09-28 | Enanta Pharm Inc | MACROCYCLIC INHIBITORS OF THE OXIMYL TYPE OF HEPATITIS C VIRUS SERINE PROTEASE |
| WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
| EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
| WO2009085978A1 (en) | 2007-12-20 | 2009-07-09 | Enanta Pharceuticals, Inc. | Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| TWI487522B (zh) | 2007-12-21 | 2015-06-11 | 賽基艾維洛米斯研究股份有限公司 | Ｈｃｖ蛋白酶抑制劑及其用途（一） |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| RU2515318C2 (ru) | 2007-12-21 | 2014-05-10 | Авила Терапьютикс, Инк. | Ингибиторы протеазы вируса гепатита с и их применение |
| CA2714604A1 (en) * | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Macrocyclic hcv ns3 protease inhibitors |
| CN102015652A (zh) | 2008-03-20 | 2011-04-13 | 益安药业 | 作为丙型肝炎病毒抑制剂的氟化大环化合物 |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2009134624A1 (en) | 2008-04-28 | 2009-11-05 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2300491B1 (en) | 2008-05-29 | 2016-01-06 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EA019327B1 (ru) | 2008-07-22 | 2014-02-28 | Мерк Шарп Энд Домэ Корп. | Макроциклическое хиноксалиновое соединение в качестве ингибитора протеазы вгс ns3 |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR20110114582A (ko) | 2008-12-19 | 2011-10-19 | 길리애드 사이언시즈, 인코포레이티드 | Ｈｃｖ ｎｓ３ 프로테아제 억제제 |
| CN102271699A (zh) | 2009-01-07 | 2011-12-07 | 西尼克斯公司 | 用于治疗hcv和hiv感染的环孢菌素衍生物 |
| TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| US8936781B2 (en) | 2009-05-13 | 2015-01-20 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis C virus inhibitors |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
| EP2461811B1 (en) | 2009-08-05 | 2016-04-20 | Idenix Pharmaceuticals LLC. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| US9193740B2 (en) | 2009-10-19 | 2015-11-24 | Enanta Pharmaceuticals, Inc. | Bismacrocyclic compounds as hepatitis C virus inhibitors |
| AU2011268498A1 (en) | 2010-06-24 | 2013-01-31 | Genoscience Pharma Sas | Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent |
| WO2012016186A1 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Macrocyclic kinase inhibitors and uses thereof |
| SG188618A1 (en) | 2010-09-21 | 2013-04-30 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
| WO2012061248A2 (en) | 2010-11-01 | 2012-05-10 | Rfs Pharma, Llc | Novel specific hcv ns3 protease inhibitors |
| JP6034802B2 (ja) | 2010-12-14 | 2016-11-30 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 大環状ラクタムの調製のための方法および中間体 |
| KR20140003521A (ko) | 2010-12-30 | 2014-01-09 | 이난타 파마슈티칼스, 인코포레이티드 | 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제 |
| EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
| AR085352A1 (es) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8912141B2 (en) | 2011-06-23 | 2014-12-16 | Panmed Ltd. | Treatment of hepatitis C virus |
| CA2843853A1 (en) | 2011-07-01 | 2013-01-10 | President And Fellows Of Harvard College | Macrocyclic insulin-degrading enzyme (ide) inhibitors and uses thereof |
| EP2744331A4 (en) | 2011-08-19 | 2015-01-21 | Merck Sharp & Dohme | METHOD AND INTERMEDIATE PRODUCTS FOR THE MANUFACTURE OF MACROLACTAMEN |
| UA119315C2 (uk) * | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| WO2014064534A2 (en) | 2012-10-05 | 2014-05-01 | Chrontech Pharma Ab | Injection needle, device, immunogenic compositions and method of use |
| EA025560B1 (ru) | 2012-10-19 | 2017-01-30 | Бристол-Майерс Сквибб Компани | Ингибиторы вируса гепатита с |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US9617310B2 (en) | 2013-03-15 | 2017-04-11 | Gilead Sciences, Inc. | Inhibitors of hepatitis C virus |
| US9873707B2 (en) | 2013-10-18 | 2018-01-23 | Merck Sharp & Dohme Corp. | Methods and intermediates for preparing macrolactams |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| WO2016172631A2 (en) | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| TWI658568B (zh) * | 2017-01-03 | 2019-05-01 | Leadtrend Technology Corporation | 高壓半導體元件以及同步整流控制器 |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| US11674136B2 (en) | 2018-02-09 | 2023-06-13 | President And Fellows Of Harvard College | DNA-templated macrocycle library |
| US12083099B2 (en) | 2020-10-28 | 2024-09-10 | Accencio LLC | Methods of treating symptoms of coronavirus infection with viral protease inhibitors |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
| US6128582A (en) | 1996-04-30 | 2000-10-03 | Vertex Pharmaceuticals Incorporated | Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
| EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
| ES2241157T3 (es) | 1997-08-11 | 2005-10-16 | Boehringer Ingelheim (Canada) Ltd. | Peptidos inhibidores de la hepatitis c. |
| IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
| KR100719606B1 (ko) | 1998-02-25 | 2007-05-17 | 에모리 유니버시티 | 2'-플루오로뉴클레오사이드 |
| GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
| DK1066247T3 (da) | 1998-03-31 | 2007-04-02 | Vertex Pharma | Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease |
| GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
| WO2000009546A1 (fr) | 1998-08-10 | 2000-02-24 | Hokkaido Electric Power Company, Incorporated | Preparation de glycopeptides ordinaires |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| WO2000025780A1 (en) | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| CA2377278C (en) | 1999-06-25 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Prodrugs of carbamate inhibitors of impdh |
| EP1162196A4 (en) | 1999-12-27 | 2003-04-16 | Japan Tobacco Inc | COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS |
| US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
| US6455508B1 (en) | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
| CN1427722A (zh) | 2000-02-18 | 2003-07-02 | 希拉生物化学股份有限公司 | 用核苷类似物治疗或预防黄病毒感染的方法 |
| ES2317900T3 (es) | 2000-04-05 | 2009-05-01 | Schering Corporation | Inhibidores de serina proteasa ns3 macrociclicos del virus de la hepatitis c que comprenden fragmentos n-ciclicas p2. |
| WO2001077091A2 (en) | 2000-04-05 | 2001-10-18 | Tularik Inc. | Ns5b hcv polymerase inhibitors |
| EP1964569A3 (en) | 2000-04-13 | 2009-07-22 | Pharmasset, Inc. | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| KR20080021797A (ko) | 2000-05-26 | 2008-03-07 | 이데닉스(케이만)리미티드 | 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물 |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
| JP3943015B2 (ja) | 2000-08-10 | 2007-07-11 | トラスティーズ オブ ボストン カレッジ | リサイクル可能メタセシス触媒 |
| US6955174B2 (en) | 2000-08-18 | 2005-10-18 | Uryovascular Systems, Inc. | Cryotherapy method for detecting and treating vulnerable plaque |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| US6809101B2 (en) | 2000-09-01 | 2004-10-26 | Shionogi & Co., Ltd. | Compounds having anti-hepatitis C virus effect |
| KR20090089922A (ko) | 2000-10-18 | 2009-08-24 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
| AU3659102A (en) | 2000-12-12 | 2002-06-24 | Schering Corp | Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
| WO2002048116A2 (en) | 2000-12-13 | 2002-06-20 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
| WO2002048165A2 (en) | 2000-12-15 | 2002-06-20 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| JPWO2002051425A1 (ja) | 2000-12-26 | 2004-04-22 | 三菱ウェルファーマ株式会社 | Ｃ型肝炎治療剤 |
| WO2002057425A2 (en) | 2001-01-22 | 2002-07-25 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| IL160205A0 (en) | 2001-08-14 | 2004-07-25 | Univ Tel Aviv Future Tech Dev | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| AU2002330154A1 (en) | 2001-09-28 | 2003-04-07 | Centre National De La Recherche Scientifique | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| JP2005536440A (ja) | 2001-09-28 | 2005-12-02 | イデニクス（ケイマン）リミテツド | ４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物 |
| WO2003062192A1 (en) | 2002-01-17 | 2003-07-31 | Smithkline Beecham Corporation | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors |
| GB0201179D0 (en) | 2002-01-18 | 2002-03-06 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| CA2369711A1 (en) * | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| JP2005527499A (ja) | 2002-02-13 | 2005-09-15 | メルク エンド カムパニー インコーポレーテッド | ヌクレオシド化合物を用いてオルトポックスウイルスの複製を阻害する方法 |
| AU2003232071A1 (en) | 2002-05-06 | 2003-11-17 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US20070004669A1 (en) | 2002-06-21 | 2007-01-04 | Carroll Steven S | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| EP1572945A2 (en) | 2002-06-27 | 2005-09-14 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| BR0312271A (pt) | 2002-06-28 | 2007-11-06 | Idenix Cayman Ltd | compostos, composições e seus usos para o tratamento de infecções por flaviviridae |
| PL374781A1 (en) | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| MXPA04012779A (es) | 2002-06-28 | 2005-08-19 | Idenix Cayman Ltd | Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae. |
| JP2005533108A (ja) | 2002-07-16 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体 |
| KR20050037559A (ko) | 2002-07-25 | 2005-04-22 | 마이크로로직스 바이오테크, 인코포레이티드 | 항바이러스성 ７-데아자 ｄ-뉴클레오시드 및 그의 용도 |
| JP2006507235A (ja) | 2002-08-01 | 2006-03-02 | フアーマセツト・インコーポレイテツド | フラビウイルス科ウイルス感染治療のためのビシクロ［４．２．１］ノナン系を有する化合物 |
| AU2003279797B2 (en) | 2002-09-30 | 2009-10-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
| CN1731993A (zh) | 2002-11-01 | 2006-02-08 | 维洛药品公司 | 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法 |
| US20040254159A1 (en) | 2003-02-27 | 2004-12-16 | Hasvold Lisa A. | Heterocyclic kinase inhibitors |
| WO2004101605A1 (en) | 2003-03-05 | 2004-11-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
| MXPA05010338A (es) | 2003-04-02 | 2005-11-17 | Boehringer Ingelheim Int | Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c. |
| GB0307891D0 (en) | 2003-04-04 | 2003-05-14 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
| ES2320771T3 (es) | 2003-04-16 | 2009-05-28 | Bristol-Myers Squibb Company | Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c. |
| US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| AU2004240704B9 (en) | 2003-05-21 | 2009-10-22 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
| EP2345657A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| GB0313250D0 (en) | 2003-06-09 | 2003-07-16 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| ATE346078T1 (de) | 2003-06-19 | 2006-12-15 | Hoffmann La Roche | Verfahren zur herstellung von 4'- azidonukleosidderivaten |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| GB0321003D0 (en) | 2003-09-09 | 2003-10-08 | Angeletti P Ist Richerche Bio | Compounds, compositions and uses |
| GB0323845D0 (en) | 2003-10-10 | 2003-11-12 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP1730167B1 (en) | 2004-01-21 | 2011-01-12 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
| HRP20090250T1 (hr) | 2004-02-24 | 2009-06-30 | Japan Tobacco | Kondenzirani heterociklički spojevi i njihova upotreba kao inhibitora hcv polimeraze |
| GB0413087D0 (en) | 2004-06-11 | 2004-07-14 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0416396D0 (en) | 2004-07-22 | 2004-08-25 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| DE602005015466D1 (de) | 2004-08-23 | 2009-08-27 | Hoffmann La Roche | Antivirale 4'-azidonucleoside |
| GB0419850D0 (en) | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| EP1807403A2 (en) | 2004-10-26 | 2007-07-18 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Tetracyclic indole derivatives as antiviral agents |
| CA2606195C (en) | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
| GB0509326D0 (en) | 2005-05-09 | 2005-06-15 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| AR057456A1 (es) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
| NZ565269A (en) | 2005-08-01 | 2010-03-26 | Merck & Co Inc | Macrocyclic peptides as HCV NS3 protease inhibitors |
| WO2007028789A1 (en) | 2005-09-07 | 2007-03-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Quinazoline derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0519797D0 (en) | 2005-09-29 | 2005-11-09 | Istituto Di Ricerche D Biolog | Therapeutic agents |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US20090203008A1 (en) | 2006-06-08 | 2009-08-13 | Ludmerer Steven W | Rapid method to determine inhibitor sensitivity of NS3/4A protease sequences cloned from clinical samples |
| GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| CA2667146C (en) | 2006-10-24 | 2016-01-19 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| AU2007309546A1 (en) | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
| AU2007309488B2 (en) | 2006-10-24 | 2012-10-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| BRPI0718161A2 (pt) | 2006-10-27 | 2013-11-26 | Merck & Co Inc | Composto, composição farmacêutica, e, uso do composto. |
| US8377874B2 (en) | 2006-10-27 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| CN101557910B (zh) | 2006-11-09 | 2011-08-17 | 双刃技术控股瑞典股份公司 | 毂装置 |
| EP2481807A3 (en) | 2007-03-09 | 2013-04-03 | Merck Sharp & Dohme Corp. | In vivo HCV resistance to anti-viral inhibitors |
| CA2691444C (en) | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| AU2008277377B2 (en) | 2007-07-19 | 2013-08-01 | Msd Italia S.R.L. | Macrocyclic compounds as antiviral agents |
| US8304385B2 (en) | 2007-11-14 | 2012-11-06 | Enanta Pharmaceuticals, Inc. | Macrocyclic tetrazolyl hepatitis C serine protease inhibitors |
| CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
-
2006
- 2006-07-28 NZ NZ565269A patent/NZ565269A/en unknown
- 2006-07-28 EP EP06800513A patent/EP1913016B1/en not_active Not-in-force
- 2006-07-28 CA CA2615896A patent/CA2615896C/en not_active Expired - Fee Related
- 2006-07-28 US US11/989,886 patent/US8278322B2/en active Active
- 2006-07-28 WO PCT/US2006/029635 patent/WO2007016441A1/en not_active Ceased
- 2006-07-28 AU AU2006275605A patent/AU2006275605B2/en not_active Ceased
- 2006-07-28 JP JP2008525069A patent/JP4705984B2/ja not_active Expired - Fee Related
- 2006-07-28 RU RU2008107972/04A patent/RU2008107972A/ru not_active Application Discontinuation
- 2006-07-28 MX MX2008001588A patent/MX2008001588A/es unknown
- 2006-07-28 KR KR1020087002861A patent/KR20080036598A/ko not_active Withdrawn
- 2006-07-28 BR BRPI0614205A patent/BRPI0614205A2/pt not_active IP Right Cessation
-
2008
- 2008-01-31 EC EC2008008157A patent/ECSP088157A/es unknown
- 2008-01-31 IL IL189166A patent/IL189166A0/en unknown
- 2008-02-14 CR CR9731A patent/CR9731A/es not_active Application Discontinuation
- 2008-02-25 MA MA30689A patent/MA29757B1/fr unknown
- 2008-02-29 NO NO20081086A patent/NO20081086L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1913016A1 (en) | 2008-04-23 |
| AU2006275605A1 (en) | 2007-02-08 |
| MX2008001588A (es) | 2008-02-19 |
| US20110028494A1 (en) | 2011-02-03 |
| JP2009503080A (ja) | 2009-01-29 |
| NZ565269A (en) | 2010-03-26 |
| MA29757B1 (fr) | 2008-09-01 |
| ECSP088157A (es) | 2008-02-20 |
| JP4705984B2 (ja) | 2011-06-22 |
| CR9731A (es) | 2008-04-10 |
| WO2007016441A1 (en) | 2007-02-08 |
| CA2615896C (en) | 2012-11-13 |
| US8278322B2 (en) | 2012-10-02 |
| EP1913016B1 (en) | 2013-01-16 |
| AU2006275605B2 (en) | 2011-01-06 |
| RU2008107972A (ru) | 2009-09-10 |
| CA2615896A1 (en) | 2007-02-08 |
| KR20080036598A (ko) | 2008-04-28 |
| BRPI0614205A2 (pt) | 2016-11-22 |
| IL189166A0 (en) | 2008-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20081086L (no) | Makrosykliske peptider som HCV NS3-proteaseinhibitorer | |
| NO20080879L (no) | HCV-NS3-proteaseinhibitorer | |
| NO20092053L (no) | HCV NS3-proteaseinhibitorer | |
| WO2006119061A3 (en) | Hcv ns3 protease inhibitors | |
| WO2008051477A3 (en) | Hcv ns3 protease inhibitors | |
| WO2008057208A3 (en) | Hcv ns3 protease inhibitors | |
| WO2008051514A3 (en) | Hcv ns3 protease inhibitors | |
| WO2008051475A3 (en) | Hcv ns3 protease inhibitors | |
| MY152070A (en) | Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors | |
| MX2011006631A (es) | Inhibidores de proteasa ns3 del virus hcv. | |
| NO20073105L (no) | Pyridazinonforbindelser | |
| EA200900969A1 (ru) | Макроциклические ингибиторы протеазы гепатита с | |
| NO20090453L (no) | Hepatitt C Virusinhibitorer | |
| EA200802346A1 (ru) | Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с | |
| ATE469155T1 (de) | Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer | |
| ATE483712T1 (de) | Hcv-ns5b-inhibitoren | |
| NO20090438L (no) | Hepatit C virus inhibitorer | |
| ATE474827T1 (de) | Hcv-replikationshemmer | |
| NO20090447L (no) | Hepatittt C virusinhibitorer | |
| NO20044808L (no) | Heterosykliske sulfonamider som er hepatitt C virus inhibitorer | |
| EA200901101A1 (ru) | Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс | |
| ATE512971T1 (de) | Peptidanaloga als hepatitis c-hemmer | |
| NO20080540L (no) | HCV-inhibitorer | |
| DK2209789T3 (da) | Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere | |
| WO2010034105A8 (en) | Hepatitis c inhibitor compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |